Olema Pharmaceuticals
OLMA
76 hedge funds and large institutions have $1.01B invested in Olema Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 27 increasing their positions, 16 reducing their positions, and 9 closing their positions.
89% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 9
69% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 16
10% more funds holding
Funds holding: 69 → 76 (+7)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
0.31% less ownership
Funds ownership: 93.19% → 92.88% (-0.31%)
3% less capital invested
Capital invested by funds: $1.05B → $1.01B (-$34.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$23.5M |
| 2 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$8.58M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.55M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$6.82M |
| 5 |
Nuveen
Charlotte,
North Carolina
|
+$6.74M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$24.5M |
| 2 |
Janus Henderson Group
London,
|
-$20.2M |
| 3 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$17.4M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$11.5M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$8.4M |
OLMA Hedge Fund Activity: Q3 2021 in Review
76 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Olema Pharmaceuticals (OLMA) for Q3 2021, worth a combined $1.01B — down 3.3% from $1.05B a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new OLMA positions and 9 closed out — a net gain of 8 holders — while 27 added to existing stakes and 16 trimmed.
The largest buyer was BlackRock, adding an estimated $23.5M. The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $24.5M sold.
- 76 institutional investors held Olema Pharmaceuticals (OLMA) as of Q3 2021, up from 69 in Q2 2021.
- Funds reported $1.01B of Olema Pharmaceuticals stock for Q3 2021, down 3.3% quarter-over-quarter.
- 17 funds opened new Olema Pharmaceuticals positions in Q3 2021 and 9 closed out, a net change of +8 holders.
- The largest Olema Pharmaceuticals buyer in Q3 2021 was BlackRock, an estimated $23.5M added.
- The largest Olema Pharmaceuticals seller in Q3 2021 was Avoro Capital Advisors, an estimated $24.5M sold.
Based on aggregated 13F filings for Q3 2021.